文献速递免疫规划卫生政策与健康促进

使用肾上腺素处理COVID-19疫苗接种后疑似过敏反应:一项澳大利亚回顾性队列研究

Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
PubMed 文献 · Vaccine · 2023-08-24

该研究分析了澳大利亚新南威尔士州2021年2月22日至9月30日期间接种COVID-19疫苗后接受肾上腺素的222例报告,按Brighton协作组过敏反应病例定义(BCCD)分级,比较临床表现、处理及再接种结局。结果显示仅32例(14%)符合BCCD 1级,176例(79%)后续接种,其中89例(51%)使用相同疫苗配方,仅14例(8%)出现另一过敏不良事件,9例(5%)再次使用肾上腺素。结论认为接受肾上腺素者中不足五分之一符合1级过敏反应标准,许多反应诊断确定性低,再接种耐受性高,需加强客观症状教育以合理使用肾上腺素。

要点

  • 222例接种后使用肾上腺素者中,仅32例(14%)符合BCCD 1级过敏反应。
  • 176例(79%)后续接种,89例(51%)用相同疫苗,14例(8%)出现另一过敏不良事件。
  • 常见症状为咽喉紧闭感(116例,52%)、呼吸困难(82例,37%)、恶心(55例,25%)。

核心结论

  • 接受肾上腺素者中不足五分之一符合BCCD 1级过敏反应标准,许多反应诊断确定性低,再接种耐受性高。
  • 需要加强关于过敏反应客观体征和症状的认识和教育,以确保肾上腺素的适当使用。

研究设计与样本

  • 澳大利亚新南威尔士州回顾性队列研究, examine 2021年2月22日至2021年9月30日接种COVID-19疫苗后接受肾上腺素的病例报告。
  • 按Brighton协作组过敏反应病例定义(BCCD)分级,比较临床表现、处理及再接种结局。

主要发现

  • 共222例接受肾上腺素,其中BCCD 1级32例(14%)、2级59例(27%)、3级2例(1%)、4级97例(44%)、5级32例(14%)。
  • 最常见症状为咽喉紧闭感(n=116,52%)、呼吸困难(n=82,37%)、恶心(n=55,25%)。
  • 176例(79%)后续接种,其中89例(51%)使用相同疫苗配方,14例(8%)出现另一过敏不良事件,9例(5%)接受肾上腺素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The rate of anaphylaxis following COVID-19 vaccinations is estimated to be 2-11 cases per million doses administered. However, adrenaline is occasionally used in individuals who are later diagnosed with immunisation stress-related responses, as their initial presenting signs and symptoms can appear similar to that of anaphylaxis. This study aims to describe the clinical profile of individuals who had received adrenaline following a COVID-19 vaccine and their subsequent revaccination outcomes. METHODS: We examined notifications of cases who had received adrenaline following a COVID-19 vaccine in New South Wales, Australia. The cases were classified into Brighton Collaboration Case Definition (BCCD) for anaphylaxis, their clinical presentation, management and subsequent revaccination outcomes were compared. RESULTS: From 22 February 2021 to 30 September 2021, there were 222 cases where adrenaline was administered. Of these, 32 (14 %) fulfilled Level 1 BCCD, 59 (27%) Level 2, 2 (1%) Level 3, 97 (44%) Level 4 and 32 (14 %) Level 5. The most commonly reported symptoms were sensation of throat closure (n = 116, 52%), difficulty breathing (n = 82, 37%) and nausea (n = 55, 25 %). Of the 176 (79%) individuals who proceeded to further vaccination, 89 (51%) received the same vaccine formulation and only 14 (8%) experienced another allergic adverse event with 9 (5%) receiving adrenaline. CONCLUSION: Less than one in five individuals who received adrenaline met Level 1 BCCD criteria for anaphylaxis. Many reactions that were treated with adrenaline had little to no diagnostic certainty of anaphylaxis and in such cases repeat vaccination had a high likelihood of being tolerated. Increased awareness and education on objective signs and symptoms of anaphylaxis is required to ensure appropriate use of adrenaline.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Deng L, Tapper K, Thosar D, et al. Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study. Vaccine. 2023. PMID: 37633752. doi:10.1016/j.vaccine.2023.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。